{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}],"title":"Grade 3"},{"measurements":[{"groupId":"OG000","value":"41"}],"title":"Not graded"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"}],"units":"Participants"}],"description":"G3 - Predominantly solid or entirely undifferentiated carcinoma. Not graded - tumor grade not reported.","groups":[{"description":"Thalidomide 200 mg PO once a day initial dose (each 28-day period will be considered one cycle). Dose increased by 200 mg every 2 weeks to maximum dose of 1000 mg/day until disease progression or adverse effects prohibit further therapy.","id":"OG000","title":"Thalidomide"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Eligible and evaluable patients","reportingStatus":"POSTED","timeFrame":"Baseline","title":"Initial Histologic Grade","type":"SECONDARY","unitOfMeasure":"Participants"}